Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma

PHASE1CompletedINTERVENTIONAL
Timeline

Start Date

January 5, 2001

Primary Completion Date

January 10, 2005

Study Completion Date

December 1, 2007

Conditions
Brain and Central Nervous System Tumors
Interventions
DRUG

irinotecan hydrochloride

DRUG

temozolomide

Trial Locations (9)

10021

Memorial Sloan-Kettering Cancer Center, New York

15232

Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh

53792

University of Wisconsin Comprehensive Cancer Center, Madison

90095

Jonsson Comprehensive Cancer Center, UCLA, Los Angeles

94143

UCSF Comprehensive Cancer Center, San Francisco

20892-1182

Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda

02115

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston

77030-4009

University of Texas - MD Anderson Cancer Center, Houston

78284-6220

University of Texas Health Science Center at San Antonio, San Antonio

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT00006025 - Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma | Biotech Hunter | Biotech Hunter